Loading...
OTCM
CLCS
Market cap38mUSD
Jul 09, Last price  
0.86USD
1D
-9.41%
1Q
2.89%
Jan 2017
91.25%
IPO
-44.48%
Name

Cell Source Inc

Chart & Performance

D1W1MN
OTCM:CLCS chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
13.31%
Rev. gr., 5y
%
Revenues
0k
Net income
-5m
L-2.79%
0-25,627-4,057,000-2,504,000-968,000-3,083,000-2,117,000-4,475,000-4,560,000-5,472,000-5,168,000-5,321,000-4,771,046-4,638,079
CFO
-3m
L+1.76%
0-23,383-3,119,662-2,000,610-1,494,060-2,287,814-2,002,114-2,587,212-2,774,631-3,378,682-3,138,686-2,347,891-2,684,162-2,731,434

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
IPO date
Jan 14, 2014
Employees
1
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT